

Gynecologic Oncology Group Study 229C: Personal Reflection

Kimberly K. Leslie, MD^{1,2}



Dr. Leslie is Chair of Obstetrics and Gynecology at the University of Iowa. In addition to her clinical and administrative responsibilities, she maintains a productive translational research laboratory.

I heard the statistician say, “The drug does not have sufficient activity to study further in this population.” It was my co-investigator on GOG study 229C, *Gefitinib in the Treatment of Advanced and Recurrent Endometrial Cancer* (see related extended abstract in this issue*), calling from Roswell Park in Buffalo. He had just completed the analysis of data from 26 women treated on our study – a study which had been five years in the making from concept to clinical trial.

These are the most damning words a clinical investigator can hear. I thought back to the beginning, when our preclinical studies indicated a new molecular agent, gefitinib, a member of a class of small molecules which blocks the epidermal growth factor receptor, could kill cancer cells in the laboratory. I sold the idea to use the drug for patients with endometrial cancer to the NIH and the pharmaceutical company based upon this rosy picture of activity. I thought about the seed money we used to initiate the trial, which had come from the family of a patient who had died of the disease, Barbara Beach. The family had so hoped that gefitinib would do for others what previous treatments failed

¹The Department of Obstetrics and Gynecology and ²Holden Comprehensive Cancer Center, Roy J. and Lucille A. Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.

Please cite this paper as: Leslie KK. Gynecologic Oncology Group Study 229C: Personal Reflection. *Proc Obstet Gynecol.* 2013;3(3 Suppl):Article 2 [2 p.]. Available from: <http://ir.uiowa.edu/pog/>. Free full text article.

Corresponding author: Kimberly K. Leslie, Department of Obstetrics and Gynecology, University of Iowa, 200 Hawkins Drive, Iowa City, IA 42242. kimberly-leslie@uiowa.edu

This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

to do for their mother. They donated \$250,000.00 in her honor to support this trial!

Then I thought about the patients – 26 women who had failed all other therapies and hoped against hope to find a cure in gefitinib. After all, hadn't we shown them the laboratory data? Hadn't we believed ourselves that we had found a breakthrough agent? As the lead investigator, I was blinded to their names and their clinical outcomes until the very end of the study....I knew them only as numbers, like G17982, etc. I knew them only as the blocks of tumor tissues sent to my laboratory to study. The assays had appeared promising on the tissues – why didn't it work in the patients??

I said to my colleague, "I can't believe that gefitinib didn't help anyone – it just doesn't seem possible given our preliminary data." He replied, "What I meant to say is that the drug does not have more activity than standard chemotherapy. That doesn't necessarily mean that no one benefited. Let me see.....oh yes, I meant to mention that patient G55394 had a complete response."

"You said a complete response? You mean she is cured? What does that really mean if the drug is not active?"

"She had a recurrent tumor nodule which has now disappeared," he said in a matter of fact statistical tone. "But that doesn't guarantee that it was as a result of the drug, you know."

I often think of Mrs. G55394 and hope she enjoyed the years she lived after taking gefitinib – I hope she enjoyed her

family and all of the important things in life. I will never know her personally, but she is a big part of my life even now. Cancer will never be cured by a single drug; I know that now as does everybody in the field. Nevertheless, some agents work very well for unique tumors, and it is now our goal to understand why.

**See "A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study. Proceedings in Obstetrics and Gynecology, 2013; 3(3 Suppl):5." An abstract of Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jun;129(3):486-94. doi: 10.1016/j.ygyno.2013.02.019. Epub 2013 Feb 21. PubMed PMID: 23438670*